Electronic Supplementary Material (ESI) for Organic & Biomolecular Chemistry. This journal is © The Royal Society of Chemistry 2018

S1

#### **Supporting Information**

# Discovery of a Novel Dipeptidyl Boronic Acid Proteasome Inhibitor for the Treatment of Multiple Myeloma and Triple-negative Breast Cancer

Meng Lei,<sup>\*a</sup> Huayun Feng,<sup>a</sup> Enhe Bai,<sup>b</sup> Hui Zhou,<sup>b</sup> Jia Wang,<sup>c</sup> Yanru Qin,<sup>d</sup> Haoyang Zhang,<sup>b</sup> Xueyuan Wang,<sup>b</sup> Zhaogang Liu,<sup>c</sup> Ou Hai,<sup>c</sup> Jia Liu<sup>c</sup> and Yongqiang Zhu<sup>\*b</sup>

<sup>a</sup> College of Science, Nanjing Forestry University, No. 159 Longpan Road, Nanjing 210037, PR China, <sup>b</sup> College of Life Science, Nanjing Normal University, No. 1 Wenyuan Road, Nanjing 210037, PR China, <sup>c</sup> Jiangsu Chia Tai Fenghai Pharmaceutical Co. Ltd., No. 9 Weidi Road, Nanjing 210046, PR China, <sup>d</sup> School of Bio-engineering, Qilu University of Technology (Shandong Academy of Sciences), No. 3501 Daxue Rd. Changqing District, Jinan, 250353, PR China \*To whom correspondence should be addressed.

\*Dr. Meng Lei

Phone: 86-25-85428652; E-mail: hk-lm@163.com

\*Prof. Yongqiang Zhu

Phone: 86-25-85891591; Fax: 86-25-85891591; E-mail: zhyqscu@163.com

#### **Contents:**

1. <sup>1</sup> H NMR and mass spectra of intermediates	S2-S15
2. <sup>1</sup> H NMR, <sup>13</sup> C NMR and mass data of final compounds	S16-S22
3. <sup>1</sup> H NMR spectra of intermediate compounds	S23-S38
4. <sup>1</sup> H NMR and <sup>13</sup> C NMR spectra of final compounds	S39-S58

#### 1. <sup>1</sup>H NMR and mass spectra of intermediates

N-ethoxycarbonylphthalimide (2a)



To a solution of phthalimide (7.36 g, 50 mmol) dissolved in anhydrous DMF (25 mL) was added TEA (9 mL, 65 mmol). Then temperature of the reaction system was cooled to 0 °C and ethyl chloroformate (5.7 mL, 60 mmol) was added dropwise. The mixture stirred at room temperature for 2 h and poured into iced water, filtered. The solid was washed with cold water and dried to obtain 8.67 g (79.1% yield) of white solid. mp 81.4-83.6 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  1.44 (s, 3H), 4.48 (q, *J* = 7.1 Hz, 2H), 7.80-7.85 (m, 2H), 7.93-7.99 (m, 2H). MS (ESI) m/z 220.1 [M+H]<sup>+</sup>.

#### (S)-2-phthalimidopropionic acid (2b)



To a stirred solution of **2a** in H<sub>2</sub>O (100 mL) was added *L*-alanine (8.9 g, 100 mmol) and Na<sub>2</sub>CO<sub>3</sub> (10.6 g, 100 mmol). After 1.5 h, the aqueous solution was slowly acidified with aqueous HCl (1N) until pH = 1-2 and filtered to obtain 17.4 g (79.3% yield) of white solid. mp 145.8-146.6 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  1.71 (s, 3H), 5.02 (q, *J* = 7.4 Hz, 1H), 7.69-7.75 (m, 2H), 7.82-7.88 (m, 2H). MS (ESI) m/z 218.2 [M-H]<sup>-</sup>.

(S)-2-(1,3-dioxoisoindolin-2-yl)-N-(quinolin-8-yl)propanamide (2c)



To a solution of **2b** (17.4 g, 79.3 mmol) in anhydrous  $CH_2Cl_2$  (80 mL) was added thionyl chloride (29 mL, 396 mmol) and the resulting solution was refluxed for 6 h. The solvent was evaporated to give yellow oil. DIPEA (20.5 g, 159 mmol) and 8aminoquinoline (11.4 g, 79.3 mmol) was dissolved in anhydrous  $CH_2Cl_2$  (103 mL) and the obtained yellow oil dissolved in CH<sub>2</sub>Cl<sub>2</sub> (30 mL) was added dropwise at -20 °C for 1 h and then allowed to react at room temperature overnight. After evaporation and purification by column chromatography using petroleum ether/EtOAc/CH<sub>2</sub>Cl<sub>2</sub> (5:1:1) as eluent, an orange solid (18.7g, 71.9%) was obtained. mp 180.0-181.9°C. <sup>1</sup>H NMR ( 400 MHz, CDCl<sub>3</sub>)  $\delta$  1.98 (s, 3H,), 5.27 (q, *J* = 7.5 Hz, 1H), 7.42 (dd, *J*<sub>1</sub> = 4.2 Hz, *J*<sub>2</sub> = 8.3 Hz, 1H), 7.51 (s, 1H), 7.53 (d, *J* = 9.0, 1H,), 7.65-7.85 (m, 2H), 7.90 (dd, *J*<sub>1</sub> = 3.6, *J*<sub>2</sub> = 7.1 Hz, 2H), 8.15 (d, *J* = 8.3 Hz, 1H,), 8.69 (d, *J* = 4.2 Hz, 1H), 8.73 (dd, *J*<sub>1</sub> = 4.7, *J*<sub>2</sub> = 8.9 Hz, 1H), 10.33 (s, 1H). MS (ESI) m/z 346.0 [M+H]<sup>+</sup>. **(S)-3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-(1,3-dioxoisoindolin-2-yl)-N-**

(quinolin-8-yl)propanamide (2d)



To a solution of **2c** (5.2 g, 15 mmol) in t-BuOH (105 mL) was added 6-iodo-2,3dihydro-1,4-benzodioxine (5.9 g, 22.5 mmol), Pd(OAc)<sub>2</sub> (337 mg, 1.5 mmol) and AgBF<sub>4</sub> (3.65 g, 18.8 mmol). The resulting solution was stirred at 85 °C for 24 h. After cooling to room temperature, the reaction was diluted with dichloromethane (100 mL) and triethylamine (6 mL) was added to the mixture. The mixture was maintained for 6 hours and then filtered through a pad of Celite. After evaporation and purification by column chromatography using petroleum ether/EtOAc/CH<sub>2</sub>Cl<sub>2</sub> (7:1:1) as eluent, an orange solid (4.8g, 66.7%) was obtained. mp 178.3-179.9 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  3.54-3.81 (m, 2H), 4.06-4.26 (m, 4H), 5.38 (dd,  $J_1$  = 6.6 Hz,  $J_2$  = 9.9 Hz, 1H), 6.74 (dd,  $J_1$  = 5.0 Hz,  $J_2$  = 16.7 Hz, 2H), 6.83 (d, J = 1.7 Hz, 1H), 7.40 (dd,  $J_1$  = 4.2 Hz,  $J_2$  = 8.3 Hz, 1H), 7.45-7.56 (m, 2H), 7.65-7.79 (m, 2H), 7.80-7.90 (m, 2H), 8.12 (dd,  $J_1$  = 1.5 Hz,  $J_2$  = 8.3 Hz, 1H), 8.63 (dd,  $J_1$  = 1.5 Hz,  $J_2$  = 4.2 Hz, 1H), 8.68-8.78 (m, 1H), 10.29 (s, 1H). MS (ESI) m/z 477.9 [M-H]<sup>-</sup>.

(S)-methyl3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-(1,3-dioxoisoindolin-2yl)propanoate (2e)



To a 120 mL sealed bottle was added **2d** (2 g, 4.2 mmol), BF<sub>3</sub>·Et<sub>2</sub>O (5.3 mL, 42 mmol) and anhydrous methanol (96 mL). The mixture was stirred at 100 °C for 25 hours. After cooling to room temperature, Et<sub>3</sub>N (8.8 mL, 63 mmol) was added dropwise. After evaporation of the solvent and dissolved in CH<sub>2</sub>Cl<sub>2</sub> (50 mL), the solution was washed with 10% hydrochloric acid, 5% NaHCO<sub>3</sub> and brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. After evaporation and purification by column chromatography (petroleum ether:EtOAc:CH<sub>2</sub>Cl<sub>2</sub> = 7:1:1), 1 g (65.3% yield) of yellow oil was obtained. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  3.35-3.55 (m, 2H), 3.77 (s, 3H), 4.17 (d, *J* = 7.0 Hz, 4H), 5.09 (dd, *J*<sub>1</sub> = 5.4 Hz, *J*<sub>2</sub> = 11.0 Hz, 1H), 6.60 (d, *J* = 8.2 Hz, 1H), 6.66 (d, *J* = 8.5 Hz, 1H), 6.68 (s, 1H), 7.71 (d, *J* = 3.6 Hz, 2H), 7.80 (d, *J* = 3.4 Hz, 2H). MS (ESI) m/z 368.4 [M+H]<sup>+</sup>.

(S)-methyl 2-amino-3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)propanoate (2f)



To a solution of **2e** (0.89 g, 2.4 mmol) in anhydrous methanol (23 mL) was added ethylenediamine (0.36 g, 6.1 mmol) and the resulting solution was refluxed for 9 h. The insoluble material was filtered off and the filtrate was evaporated and purified by column chromatography using petroleum ether/EtOAc/CH<sub>2</sub>Cl<sub>2</sub> (4:1:1) as eluent to give yellow oil 373 mg (yield 64.9%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  2.74 (dd,  $J_1 = 7.9$  Hz,  $J_2 = 13.6$  Hz, 1H), 2.98 (dd,  $J_1 = 5.0$  Hz,  $J_2 = 13.6$  Hz, 1H), 3.67 (dd,  $J_1 = 5.0$  Hz,  $J_2 = 7.9$  Hz, 1H), 3.72 (s, 3H), 4.18-4.26 (m, 4H), 6.64 (dd,  $J_1 = 2.0$  Hz,  $J_2 = 8.2$  Hz, 1H), 6.69 (d, J = 2.0 Hz, 1H), 6.78 (d, J = 8.2 Hz, 1H). MS (ESI) m/z 238.2 [M+H]<sup>+</sup>.

Compounds **3d-3f** were prepared following a similar procedure described for the synthesis of **3a**.

(S)-2-(2,5-dichlorobenzamido)-3-(2,3-dihydrobenzo[*b*][1,4]dioxin-6-yl)propanoic acid (3d)



White solid (0.84 g, 88.4%). mp 194.8-196.6 °C. <sup>1</sup>H NMR (400 MHz, DMSO- $d_6$ )  $\delta$  2.80 (dd,  $J_I = 10.4$  Hz,  $J_2 = 13.8$  Hz, 1H), 3.06 (dd,  $J_I = 4.6$  Hz,  $J_2 = 13.9$  Hz, 1H), 4.20 (s, 4H), 4.48-4.53 (m, 1H), 6.73 (dd,  $J_I = 1.8$  Hz,  $J_2 = 8.3$  Hz, 1H), 6.76 (d, J = 8.1 Hz, 1H), 6.78 (d, J = 1.7 Hz, 1H), 7.15-7.22 (m, 1H), 7.47-7.57 (m, 2H), 8.84 (d, J = 8.2 Hz, 1H), 12.94 (s, 1H). MS (ESI) m/z 393.8 [M-H]<sup>-</sup>.

(S)-3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-(5,6,7,8-tetrahydronaphthalene-1carboxamido)propanoic acid (3e)



White solid (0.32 g, 84.5%). mp 190.9-192.3 °C. <sup>1</sup>H NMR (400 MHz, DMSO- $d_6$ )  $\delta$  1.54-1.72 (m, 4H), 2.26-2.58 (m, 2H), 2.71 (t, J = 6.1 Hz, 2H), 2.78 (dd,  $J_1 = 10.6$ Hz,  $J_2 = 13.7$  Hz, 1H), 3.04 (dd,  $J_1 = 4.2$  Hz,  $J_2 = 13.7$  Hz, 1H), 4.19 (s, 4H), 4.42-4.54 (m, 1H), 6.71 (d, J = 8.3 Hz, 1H), 6.75 (d, J = 8.2 Hz, 1H), 6.77 (s, 1H), 6.93 (dd,  $J_1 = 4.3$  Hz,  $J_2 = 8.4$  Hz, 1H), 7.04-7.13 (m, 2H), 8.29 (d, J = 7.9 Hz, 1H), 12.91 (s, 1H). MS (ESI) m/z 380.2 [M-H]<sup>-</sup>.

(S)-3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-(pyrazine-2-

carboxamido)propanoic acid (3f)



White solid (0.31 g, 90.9%). mp 176.3-178.1 °C. <sup>1</sup>H NMR (400 MHz, DMSO- $d_6$ )  $\delta$  3.00-3.16 (m, 2H), 4.09-4.25 (m, 4H), 4.63 (dd,  $J_1$  = 7.1 Hz,  $J_2$  = 13.9 Hz, 1H), 6.66 (dd,  $J_1$  = 1.9 Hz,  $J_2$  = 8.3 Hz, 1H), 6.71 (dd,  $J_1$  = 5.1 Hz,  $J_2$  = 6.7 Hz, 2H), 8.75 (dd,  $J_1$ = 1.5 Hz,  $J_2$  = 2.4 Hz,1H), 8.84 (d, J = 8.1 Hz, 1H), 8.89 (d, J = 2.5 Hz, 1H), 9.15 (d, J = 1.4 Hz, 1H), 13.10 (s, 1H). MS (ESI) m/z 328.2 [M-H]<sup>-</sup>.

2-amino-N-((R)-3-methyl-1-((3aS,4S,6R,7aR)-3a,5,5-trimethylhexahydro-4,6methanobenzo[d][1,3,2]dioxaborol-2-yl)butyl)-3-phenylpropanamide hydrochloride (6a)



To a cooled solution (-10 °C) of N-Boc-L-phenyl alanine (3.4 g, 12.7 mmol) dissolved in anhydrous  $CH_2Cl_2$  (40 mL) was added HOBt (2.6 g, 19.1 mmol). After 10 min, EDCI (3.7 g, 19.1 mmol) was added. Finally, **5a** (4.8 g, 12.7 mmol) and DIPEA (5.8 g, 44.5 mmol) were added. The mixture stirred at -10 °C for 1 h and at room temperature for 15 h. The mixture was washed with 10% hydrochloric acid, 5% NaHCO<sub>3</sub>, and brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. After filtration and evaporation, the obtained crude product was directly used in the next reaction.

The prepared boronic acid ester was dissolved in ethyl acetate (22 mL) and was dropwise added 4.5 mol/L HCl in ethyl acetate (40 mL) at 0 °C. Then the mixture was stirred for 2 h at room temperature and the ethyl acetate was evaporated under vacuo. MTBE was added to the residue and filtered to obtain glassy solid **6a** (7.05 g, 80.6%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  0.80 (s, 3H), 0.81-0.86 (m, 6H), 1.20 (d, *J* = 7.0 Hz, 2H), 1.26 (s, 3H), 1.27-1.31 (m, 1H), 1.33 (s, 3H), 1.48 (d, *J* = 2.8 Hz, 1H), 1.80 (d, *J* = 15.2 Hz, 2H), 2.02 (t, *J* = 5.3 Hz, 1H), 2.06-2.15 (m, 1H), 2.22-2.32 (m, 1H), 2.92-2.95 (m, 1H), 3.31 (dd, *J*<sub>1</sub> = 13.4 Hz, *J*<sub>2</sub> = 8.0 Hz, 1H), 3.44 (dd, *J*<sub>1</sub> = 13.4 Hz, *J*<sub>2</sub> = 8.1 Hz, 1H), 4.23 (d, *J* = 8.3 Hz, 1H), 4.67-4.70 (m, 1H), 7.23 (d, *J* = 7.1 Hz, 1H), 7.26-7.30 (m, 2H), 7.35 (d, *J* = 7.0 Hz, 2H), 7.66 (s, 1H), 8.27 (s, 3H). MS (ESI) m/z 413.27 [M+H]<sup>+</sup>.

Compounds **6b-6e** were prepared from the corresponding N-boc-carboxylic acids and **5a** following the similar procedure described for the synthesis of **6a**.

2-amino-N-((R)-3-methyl-1-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6methanobenzo[d][1,3,2]dioxaborol-2-yl)butyl)acetamide hydrochloride (6b)



Glassy solid (2.17 g, 66.2%). <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>)  $\delta$  0.84 (dd, *J*<sub>1</sub> = 8.0 Hz, *J*<sub>2</sub> = 13.5 Hz, 9H), 1.19 (d, *J* = 10.6 Hz, 1H), 1.24 (s, 3H), 1.28 (s, 1H), 1.32 (s, 3H), 1.37-1.48 (m, 1H), 1.67 (dd, *J*<sub>1</sub> = 10.4 Hz, *J*<sub>2</sub> = 21.3 Hz, 2H), 1.84 (s, 1H), 1.94 (t, *J* = 4.8 Hz, 1H), 2.14 (d, *J* = 4.9 Hz, 1H), 2.21-2.33 (m, 1H), 3.00 (s, 1H), 3.51 (d, *J* = 16.4 Hz, 2H), 4.28 (d, *J* = 8.1 Hz, 1H), 8.14 (s, 3H), 8.52 (s, 1H). MS (ESI) m/z 323.4 [M+H]<sup>+</sup>.

(S)-2-amino-3,3-dimethyl-N-((R)-3-methyl-1-((3aS,4S,6S,7aR)-3a,5,5trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborol-2yl)butyl)butanamide hydrochloride (6c)



Glassy solid (1.3 g, 87.3%). <sup>1</sup>H NMR (400 MHz, DMSO- $d_6$ )  $\delta$  0.80 (s, 3H), 0.87 (dd,  $J_1 = 3.8$  Hz,  $J_2 = 6.5$  Hz, 6H), 0.98 (s, 9H), 1.23 (s, 3H), 1.27 (dd,  $J_1 = 4.9$  Hz,  $J_2 = 9.4$  Hz, 2H), 1.30 (s, 3H), 1.37-1.47 (m, 1H), 1.64-1.74 (m, 2H), 1.80-1.86 (m, 1H), 1.90 (dd,  $J_1 = 5.1$  Hz,  $J_2 = 6.0$  Hz, 1H), 2.02-2.11 (m, 1H), 2.21-2.32 (m, 1H), 2.90-3.00 (m, 1H), 3.57 (s, 1H), 4.26 (dd,  $J_1 = 1.9$  Hz,  $J_2 = 8.7$  Hz, 1H), 8.12-8.26 (m, 3H), 8.58 (d, J = 4.0 Hz, 1H). MS (ESI) m/z 479.4 [M+H]<sup>+</sup>.

(S)-2-amino-3-(2-fluorophenyl)-N-((R)-3-methyl-1-((3aS,4S,6S,7aR)-3a,5,5trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborol-2yl)butyl)propanamide hydrochloride (6d)



Glassy solid (1.43 g, 82.5%). <sup>1</sup>H NMR (400 MHz, DMSO- $d_6$ )  $\delta$  0.78 (d, J = 6.5 Hz, 6H), 0.82 (s, 3H), 1.24 (s, 3H), 1.25-1.30 (m, 2H), 1.31 (s, 3H), 1.32-1.37 (m, 1H), 1.68 (dd,  $J_1 = 3.3$  Hz,  $J_2 = 8.8$  Hz, 1H), 1.79-1.86 (m, 1H), 1.89-1.95 (m, 2H), 2.11 (dd,  $J_1 = 5.3$  Hz,  $J_2 = 14.8$  Hz, 1H), 2.23-2.31 (m, 1H), 2.75-2.84 (m, 1H), 3.00 (dd,  $J_1 = 8.9$  Hz,  $J_2 = 13.7$  Hz, 1H), 3.12 (dd,  $J_1 = 5.6$  Hz,  $J_2 = 13.8$  Hz, 1H), 4.02 (dd,  $J_1 = 7.2$  Hz,  $J_2 = 14.3$  Hz, 1H), 4.25 (dd,  $J_1 = 1.9$  Hz,  $J_2 = 8.7$ , 1H), 7.08-7.18 (m, 2H), 7.28-7.35 (m, 2H), 8.51 (s, 3H), 8.55 (d, J = 4.8 Hz, 1H). MS (ESI): observed: m/z 431.8[M+H]<sup>+</sup>.

(S)-2-amino-3-(2,6-difluorophenyl)-N-((R)-3-methyl-1-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborol-2yl)butyl)propanamide hydrochloride (6e)



Glassy solid (0.58 g, 71.7%). <sup>1</sup>H NMR (400 MHz, DMSO- $d_6$ )  $\delta$  0.75 (dd,  $J_1$  = 3.4 Hz,  $J_2$  = 6.5 Hz, 6H), 0.81 (s, 3H), 1.13-1.17 (m, 2H), 1.17-1.21 (m, 1H), 1.24 (s, 3H), 1.30 (s, 3H), 1.65 (d, J = 14.2 Hz, 1H), 1.82 (d, J = 2.6 Hz, 1H), 1.89-1.92 (m, 2H), 2.05-2.13 (m, 1H), 2.20-2.29 (m, 1H), 2.70-2.80 (m, 1H), 3.08 (d, J = 7.5 Hz, 2H), 3.90 (d, J = 22.0 Hz, 1H), 4.21 (dd,  $J_1$  = 1.8 Hz,  $J_2$  = 8.6 Hz, 1H), 7.05 (t, J = 7.9 Hz, 2H), 7.32-7.42 (m, 1H), 8.48 (d, J = 5.2 Hz, 1H), 8.61 (s, 3H). MS (ESI) m/z 449.8 [M+H]<sup>+</sup>.

(S)-N-((R)-3-methyl-1-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6methanobenzo[d][1,3,2]dioxaborol-2-yl)butyl)-2-(2-morpholinoacetamido)-3phenylpropanamide (7a)



TEA (1.35 g, 13.4 mmol) and **6a** (1.0 g, 2.23 mmol) were dissolved in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (15 mL) and 2-morpholinoacetyl chloride (0.36 g, 2.23 mmol) was added dropwise at -0 °C and then allowed to react at room temperature for 1 h. The mixture was washed with H<sub>2</sub>O and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. After filtration, evaporation and purification by column chromatography using petroleum ether/EtOAc (2:1) as eluent to give a glassy solid 0.84 g (69.8% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  0.85 (dd, *J*<sub>1</sub> = 4.2 Hz, *J*<sub>2</sub> = 8.2 Hz, 9H), 1.28 (s, 3H), 1.40 (s, 3H), 1.41 (d, *J* = 7.3 Hz, 2H), 1.48 (dd, *J*<sub>1</sub> = 6.6 Hz, *J*<sub>2</sub> = 13.1 Hz, 1H), 1.79-1.82 (m, 1H), 1.83-1.86 (m, 1H), 1.87-1.94 (m, 2H), 2.15-2.19 (m, 1H), 2.22 (dd, *J*<sub>1</sub> = 4.4 Hz, *J*<sub>2</sub> = 9.6 Hz, 1H), 2.25-2.39 (m, 4H), 3.05-3.08 (m,1H), 3.09 (t, *J* = 3.7 Hz, 2H), 3.11-3.16 (m, 2H), 3.54-3.63 (m, 4H), 4.30 (dd, *J*<sub>1</sub> = 2.1 Hz, *J*<sub>2</sub> = 8.8 Hz, 1H), 4.67 (dd, *J*<sub>1</sub> = 7.8 Hz, *J*<sub>2</sub> = 15.3 Hz, 1H), 6.29 (d, *J* = 4.5 Hz, 1H), 7.19-7.29 (m, 5H), 7.53 (d, *J* = 7.7 Hz, 1H). MS (ESI) m/z 540.7 [M+H]<sup>+</sup>.

Compound **7b** was prepared from **6b** following the similar procedure described for the synthesis of **7a**.

N-((R)-3-methyl-1-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6methanobenzo[d][1,3,2]dioxaborol-2-yl)butyl)-2-(2morpholinoacetamido)acetamide (7b)



Glassy solid (0.53 g, 41.7%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  0.83 (s, 3H), 0.90 (dd,  $J_1 = 2.8$  Hz,  $J_2 = 6.6$  Hz, 6H), 1.27 (s, 3H), 1.38 (s, 3H), 1.45 (t, J = 7.3 Hz, 2H), 1.61 (dd,  $J_1 = 5.9$  Hz,  $J_2 = 12.7$  Hz, 1H), 1.78-1.81 (m, 1H), 1.81-1.86 (m, 1H), 2.00-2.04 (m, 2H), 2.14-2.20 (m, 1H), 2.29-2.33 (m, 1H), 2.51-2.55 (m, 4H), 3.21 (dd,  $J_1 = 7.0$  Hz,  $J_2 = 12.9$  Hz, 1H), 3.70-3.74 (m, 4H), 3.96 (t, J = 5.5 Hz, 2H), 4.28 (dd,  $J_1 = 7.0$  Hz,  $J_2 = 12.9$  Hz, 1H), 3.70-3.74 (m, 4H), 3.96 (t, J = 5.5 Hz, 2H), 4.28 (dd,  $J_1 = 7.0$  Hz,  $J_2 = 12.9$  Hz, 1H), 3.70-3.74 (m, 4H), 3.96 (t, J = 5.5 Hz, 2H), 4.28 (dd,  $J_1 = 7.0$  Hz,  $J_2 = 12.9$  Hz, 1H), 3.70-3.74 (m, 4H), 3.96 (t, J = 5.5 Hz, 2H), 4.28 (dd,  $J_1 = 7.0$  Hz,  $J_2 = 12.9$  Hz, 1H), 3.70-3.74 (m, 4H), 3.96 (t, J = 5.5 Hz, 2H), 4.28 (dd,  $J_1 = 7.0$  Hz,  $J_2 = 12.9$  Hz, 1H), 3.70-3.74 (m, 4H), 3.96 (t, J = 5.5 Hz, 2H), 4.28 (dd,  $J_1 = 7.0$  Hz,  $J_2 = 12.9$  Hz, 1H), 3.70-3.74 (m, 4H), 3.96 (t, J = 5.5 Hz, 2H), 4.28 (dd,  $J_1 = 7.0$  Hz,  $J_2 = 12.9$  Hz, 1H), 3.70-3.74 (m, 4H), 3.96 (t, J = 5.5 Hz, 2H), 4.28 (dd,  $J_1 = 7.0$  Hz,  $J_2 = 12.9$  Hz, 1H), 3.70-3.74 (m, 4H), 3.96 (t, J = 5.5 Hz, 2H), 4.28 (dd,  $J_1 = 7.0$  Hz,  $J_2 = 12.9$  Hz, 1H), 3.70-3.74 (m, 4H), 3.96 (t, J = 5.5 Hz, 2H), 4.28 (dd,  $J_1 = 7.0$  Hz,  $J_2 = 12.9$  Hz, 1H), 3.70-3.74 (m, 4H), 3.96 (t, J = 5.5 Hz, 2H), 4.28 (dd,  $J_1 = 7.0$  Hz,  $J_2 = 12.9$  Hz, 1H), 3.70-3.74 (m, 4H), 3.96 (t, J = 5.5 Hz, 2H), 4.28 (dd,  $J_1 = 7.0$  Hz,  $J_2 = 12.9$  Hz, 1H), 3.90 (dz,  $J_1 = 7.0$  Hz,  $J_2 = 12.9$  Hz, 1H), 3.90 (dz,  $J_1 = 7.0$  Hz,  $J_2 = 12.9$  Hz, 1H), 3.70-3.74 (m, 4H), 3.96 (dz,  $J_2 = 12.9$  Hz, 1H), 3.90 (dz,  $J_1 = 7.0$  Hz,  $J_2 = 12.9$  Hz, 1H), 3.90 (dz,  $J_1 = 7.0$  Hz,  $J_2 = 12.9$  Hz, 1H), 3.90 (dz,  $J_1 = 7.0$  Hz,  $J_2 = 12.9$  Hz, 1H), 3.90 (dz,  $J_1 = 7.0$  Hz,  $J_2 = 12.9$  Hz, 1H), 3.90 (dz,  $J_1 = 7.0$  Hz,  $J_2 = 12.9$  Hz

2.1 Hz, *J*<sub>2</sub> = 8.8 Hz, 1H), 4.71 (s, 1H), 6.36 (d, *J* = 3.9 Hz, 1H), 7.75 (s, 1H). MS (ESI) m/z 450.7 [M+H]<sup>+</sup>.

N-((S)-3,3-dimethyl-1-(((R)-3-methyl-1-((3aS,4S,6S,7aR)-3a,5,5trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborol-2-yl)butyl)amino)-1oxobutan-2-yl)pyrazine-2-carboxamide (7c)



To a cooled solution (-10 °C) of pyrazine-2-carboxylic acid (0.12 g, 0.9 mmol) dissolved in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (6 mL) was added HOBt (0.2 g, 1.4 mmol). After 10 min, EDCI (0.3 g, 1.4 mmol) was added. Finally (R)-3-methyl-1-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborol-2-yl)butan-1amine 2,2,2-trifluoroacetate 6c (0.4 g, 0.9 mmol) and DIPEA (0.4 g, 3.4 mmol) were added. The mixture stirred at -10 °C for 1 h and at room temperature overnight. The mixture was washed with 1N HCl, 5% NaHCO<sub>3</sub>, and brine, dried over anhydrous  $Na_2SO_4$ . After filtered, evaporation and purification with chromatography (petroleum ether/EtOAc = 3:1), 0.38 g (81.6%) of glassy solid was obtained. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  0.83 (s, 3H), 0.89 (dd,  $J_1$  = 4.7 Hz,  $J_2$  = 6.5 Hz, 6H), 1.07 (s, 9H), 1.25 (d, J = 1.8 Hz, 1H), 1.27 (s, 3H), 1.36 (s, 3H), 1.46 (t, J = 7.4 Hz, 2H), 1.58-1.68 (m, 2H), 1.87-1.93 (m, 1H), 1.98 (t, J = 5.5 Hz, 1H), 2.12-2.19 (m, 1H), 2.32 (m, 1H), 3.26 (dd,  $J_1 = 7.6$  Hz,  $J_2 = 13.1$  Hz, 1H), 4.30 (dd,  $J_1 = 2.0$  Hz,  $J_2 = 8.8$  Hz, 1H), 4.39 (d, J = 9.7Hz, 1H), 5.95 (d, J = 5.1 Hz, 1H), 8.49 (d, J = 9.7 Hz, 1H), 8.55 (dd,  $J_1 = 2.4$ ,  $J_2 = 1.5$ Hz, 1H), 8.74 (d, J = 2.4 Hz, 1H), 9.37 (d, J = 1.4 Hz, 1H). MS (ESI) m/z 485.6  $[M+H]^+$ .

Compounds **7d-7h** were prepared from the corresponding carboxylic acids and boric acid ester hydrochloride following the similar procedure described for the synthesis of **7c**.

N-((S)-3,3-dimethyl-1-(((R)-3-methyl-1-((3aS,4S,6S,7aR)-3a,5,5trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborol-2-yl)butyl)amino)-1oxobutan-2-yl)-5,6,7,8-tetrahydronaphthalene-1-carboxamide (7d)



Glassy solid (0.48 g, 81.3%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  0.80 (dd,  $J_1 = 5.9$  Hz,  $J_2 = 19.8$  Hz, 9H), 1.06 (s, 9H), 1.27 (s, 3H), 1.29 (d, J = 6.4 Hz, 2H), 1.37 (s, 3H), 1.40 (d, J = 7.4 Hz, 1H), 1.57 (dd,  $J_1 = 6.7$  Hz,  $J_2 = 13.3$  Hz, 1H), 1.77 (d, J = 4.4 Hz, 4H), 1.86 (d, J = 12.8 Hz, 2H), 2.00 (t, J = 5.5 Hz, 1H), 2.1-2.19 (m, 1H), 2.35-2.27 (m, 1H), 2.83 (d, J = 35.3 Hz, 4H), 3.12 (dd,  $J_1 = 7.5$  Hz,  $J_2 = 12.3$  Hz, 1H), 4.23-4.28 (m, 1H), 4.60 (d, J = 9.6 Hz, 1H), 6.51 (d, J = 9.5 Hz, 1H), 6.75 (d, J = 3.9 Hz, 1H), 7.12 (dd,  $J_1 = 7.0$  Hz,  $J_2 = 11.9$  Hz, 3H). MS (ESI) m/z 537.5[M+H]<sup>+</sup>. **2,5-dichloro-N-((S)-3,3-dimethyl-1-(((R)-3-methyl-1-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborol-2-yl)butyl)amino)-1-oxobutan-2-yl)benzamide (7e)** 



Glassy solid (0.31 g, 57.2%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  0.83 (s, 3H), 0.87 (dd,  $J_I = 6.6$  Hz,  $J_2 = 8.8$  Hz, 6H), 1.08 (s, 9H), 1.24 (d, J = 6.6 Hz, 2H), 1.27 (s, 3H), 1.30 (t, J = 8.1 Hz, 1H), 1.37 (s, 3H), 1.62 (dd,  $J_I = 6.6$  Hz,  $J_2 = 13.4$  Hz, 1H), 1.81-1.90 (m, 2H), 2.00 (t, J = 5.5 Hz, 1H), 2.11-2.19 (m, 1H), 2.28-2.37 (m, 1H), 3.22 (dd,  $J_I = 7.6$  Hz,  $J_2 = 13.0$  Hz, 1H), 4.28 (dd,  $J_I = 2.0$  Hz,  $J_2 = 8.8$  Hz, 1H), 4.51 (d, J = 9.3 Hz, 1H), 6.30 (d, J = 4.9 Hz, 1H), 6.88 (d, J = 9.2 Hz, 1H), 7.33 (d, J = 1.9 Hz, 2H), 7.56 (dd,  $J_I = 1.0$  Hz,  $J_2 = 1.8$  Hz, 1H). MS (ESI) m/z 551.3[M+H]<sup>+</sup>.

2,5-dichloro-N-((S)-3-(2-fluorophenyl)-1-(((R)-3-methyl-1-((3aS,4S,6S,7aR)-

3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborol-2-

yl)butyl)amino)-1-oxopropan-2-yl)benzamide (7f)



Glassy solid (0.94 g, 53.5%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  0.84 (s, 3H), 0.87 (dd,  $J_I = 3.6$  Hz,  $J_2 = 6.5$  Hz, 6H), 1.28 (s, 3H), 1.32-1.37 (m, 1H), 1.39 (s, 3H), 1.40-1.45 (m, 2H), 1.53 (dd,  $J_I = 6.5$  Hz,  $J_2 = 19.4$  Hz, 1H), 1.80-1.86 (m, 1H), 1.88-1.93 (m, 1H), 2.01-2.05 (m, 1H), 2.14-2.23 (m, 1H), 2.28-2.37 (m, 1H), 3.19 (dd,  $J_I = 7.8$  Hz,  $J_2 = 14.1$  Hz, 1H), 3.25 (dd,  $J_I = 6.7$  Hz,  $J_2 = 13.9$  Hz, 2H), 4.30 (dd,  $J_I = 2.0$  Hz,  $J_2 = 8.8$  Hz, 1H), 4.84-4.94 (m, 1H), 6.23 (d, J = 5.6 Hz, 1H), 6.84 (d, J = 8.0 Hz, 1H), 7.00-7.10 (m, 2H), 7.20-7.25 (m, 1H), 7.27-7.33 (m, 3H), 7.43 (dd,  $J_I = 0.7$  Hz,  $J_2 = 1.9$  Hz, 1H). MS (ESI) m/z 603.7 [M+H]<sup>+</sup>.

2,5-dichloro-N-((S)-3-(2,6-difluorophenyl)-1-(((R)-3-methyl-1-((3aS,4S,6S, 7aR)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborol-2yl)butyl)amino)-1-oxopropan-2-yl)benzamide (7g)



Glassy solid (0.37 g, 50.4%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  0.84 (-CH<sub>3</sub>, s, 3H), 0.90 (-CH<sub>3</sub>, dd,  $J_I = 3.9$  Hz,  $J_2 = 6.5$  Hz, 6H), 1.33 (-CH<sub>3</sub>, s, 3H), 1.37 (-CH<sub>2</sub>, dd,  $J_I =$ 5.8 Hz,  $J_2 = 11.2$  Hz, 2H), 1.40 (-CH<sub>3</sub>, s, 3H), 1.46-1.49 (-CH, m, 1H), 1.80-1.88 (-CH, m, 1H), 1.89- 1.94 (-CH, m, 1H), 1.99-2.07 (-CH<sub>2</sub>, m, 2H), 2.17-2.23 (-CH<sub>2</sub>, m, 1H), 2.29-2.38 (-CH<sub>2</sub>, m, 1H), 3.19 (-CH, dd,  $J_I = 9.7$  Hz,  $J_2 = 14.2$  Hz, 1H), 3.24-3.34 (-CH<sub>2</sub>, m, 2H), 4.31 (-CH, dd,  $J_I = 1.9$  Hz,  $J_2 = 8.8$  Hz, 1H), 4.92 (-CH, dd,  $J_I =$ 5.2 Hz,  $J_2 = 9.3$  Hz, 1H), 6.31 (-CONH, d, J = 5.7 Hz, 1H), 6.85 (-CONH, d, J = 8.3Hz, 1H), 6.89 (-Ph, d, J = 7.7 Hz, 1H), 7.17-7.25 (-Ph, m, 1H), 7.26-7.55 (-Ph, m, 4H). MS (ESI) m/z 619.8 [M-H]<sup>-</sup>. 2,5-dichloro-N-((S)-1-(((R)-3-methyl-1-((3aS,4S,6S,7aR)-3a,5,5-trimethyl hexahydro-4,6-methanobenzo[d][1,3,2]dioxaborol-2-yl)butyl)amino)-1-oxo-3phenylpropan-2-yl)benzamide (7h)



Glassy solid (0.71 g, 76.8%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  0.84 (dd,  $J_1 = 2.2$  Hz,  $J_2 = 4.0$  Hz, 9H), 1.29 (s, 3H), 1.39 (s, 3H), 1.47 (dd,  $J_1 = 6.6$  Hz,  $J_2 = 13.9$  Hz, 1H), 1.61-1.67 (m, 2H), 1.78-1.94 (m, 3H), 2.01-2.05 (m, 1H), 2.16-2.21 (m, 1H), 2.30-2.37 (m, 1H), 3.13 (dd,  $J_1 = 7.8$  Hz,  $J_2 = 13.7$  Hz, 1H), 3.17-3.27 (m, 2H), 4.30 (dd,  $J_1 = 2.0$  Hz,  $J_2 = 8.8$  Hz, 1H), 4.82 (dd,  $J_1 = 6.2$  Hz,  $J_2 = 7.8$  Hz, 1H), 5.93 (d, J = 4.7 Hz, 1H), 6.89 (d, J = 7.6 Hz, 1H), 7.22-7.34 (m, 8H), 7.48 (dd,  $J_1 = 1.0$  Hz,  $J_2 = 1.9$  Hz, 1H). MS (ESI) m/z 585.7[M+H]<sup>+</sup>.

Compounds 7k-7m and 7o-7p were prepared following a similar procedure described for the synthesis of 7i.

2,5-dichloro-N-((S)-3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-1-(((R)-3-methyl-1-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-

methanobenzo[d][1,3,2]dioxaborol-2-yl)butyl)amino)-1-oxopropan-2yl)benzamide (7k)



Glassy solid (0.14 g, 74.5%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  0.84 (d, J = 5.4 Hz, 3H), 0.87 (d, J = 6.7 Hz, 6H), 1.19 (d, J = 12.5 Hz, 1H), 1.28 (s, 3H), 1.29-1.36 (m, 1H), 1.41 (s, 3H), 1.44-1.52 (m, 1H), 1.85 (dd,  $J_I$  = 12.0 Hz,  $J_2$  = 19.5 Hz, 2H), 1.99 (dd,  $J_I$  = 8.9 Hz,  $J_2$  = 14.9 Hz, 1H), 2.04 (d, J = 3.2 Hz, 1H), 2.12-2.25 (m, 1H), 2.33 (dd,  $J_I$  = 8.5 Hz,  $J_2$  = 14.2 Hz, 1H), 2.92-3.06 (m, 1H), 3.07-3.36 (m, 2H), 4.23 (s,

4H), 4.27-4.37 (m, 1H), 4.67-4.80 (m, 1H), 5.90 (dd, *J*<sub>1</sub> = 5.1 Hz, *J*<sub>2</sub> = 56.0 Hz, 1H), 6.70-6.83 (m, 3H), 6.86 (t, *J* = 7.9 Hz, 1H), 7.30 (d, *J* = 8.5 Hz, 2H), 7.45-7.58 (m, 1H). MS (ESI) m/z 643.2 [M+H]<sup>+</sup>.

N-((S)-3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-1-(((R)-3-methyl-1-

((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-

methanobenzo[d][1,3,2]dioxaborol-2-yl)butyl)amino)-1-oxopropan-2-yl)-5,6,7,8tetrahydronaphthalene-1-carboxamide (7l)



Glassy solid (0.15 g, 85.5%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  0.84 (t, J = 3.5 Hz, 3H), 0.85-0.94 (m, 6H), 1.25 (d, J = 2.6 Hz, 1H), 1.27 (s, 3H), 1.34 (dd,  $J_I = 4.6$  Hz,  $J_2 = 11.2$  Hz, 1H), 1.43 (s, 3H), 1.52 (dd,  $J_I = 7.3$  Hz,  $J_2 = 13.6$  Hz, 1H), 1.59-1.67 (m, 1H), 1.74 (s, 4H), 1.80-1.96 (m, 2H), 1.98-2.06 (m, 1H), 2.12–2.25 (m, 1H), 2.26-2.38 (m, 1H), 2.67-2.78 (m, 4H), 2.93-3.11 (m, 2H), 3.14-3.23 (m, 1H), 4.22 (s, 4H), 4.31 (dd,  $J_I = 4.4$  Hz,  $J_2 = 9.1$  Hz, 1H), 4.66-4.83 (m, 1H), 6.12 (dd,  $J_I = 5.3$  Hz,  $J_2 = 49.1$  Hz, 1H), 6.27-6.42 (m, 1H), 6.70-6.76 (m, 1H), 6.76-6.83 (m, 2H), 6.99-7.14 (m, 3H). MS (ESI) m/z 627.3 [M-H]<sup>-</sup>.

N-((S)-3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-1-(((R)-3-methyl-1-

((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-

methanobenzo[d][1,3,2]dioxaborol-2-yl)butyl)amino)-1-oxopropan-2-

yl)pyrazine-2-carboxamide (7m)



Glassy solid (0.56 g, 85.4%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  0.82 (d, J = 2.2 Hz, 3H), 0.85 (d, J = 6.3 Hz, 6H), 0.93 (s, 1H), 1.22 (d, J = 10.8 Hz, 1H), 1.28 (s, 3H), 1.40 (s, 3H), 1.46 (dd,  $J_1 = 6.8$  Hz,  $J_2 = 13.2$  Hz, 1H), 1.66 (s, 1H), 1.79-1.93 (m, 2H), 2.02 (dd,  $J_1 = 7.3$  Hz,  $J_2 = 12.6$  Hz, 1H), 2.14-2.23 (m, 1H), 2.27-2.38 (m, 1H), 2.96-3.07 (m, 1H), 3.07-3.26 (m, 2H), 4.21 (s, 4H), 4.24-4.37 (m, 1H), 4.74 (dd,  $J_1 = 7.8$  Hz,  $J_2 = 14.3$  Hz, 1H), 5.90 (dd,  $J_1 = 5.1$  Hz,  $J_2 = 39.8$  Hz, 1H), 6.71-6.85 (m, 3H), 8.38 (dd,  $J_1 = 8.3$  Hz,  $J_2 = 14.3$  Hz, 1H), 8.54 (d, J = 5.1 Hz, 1H), 8.74 (d, J = 2.2 Hz, 1H), 9.35 (s, 1H). MS (ESI) m/z 575.3 [M-H]<sup>-</sup>.

2,5-dichloro-N-((S)-3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-1-oxo-1-(((R)-1-

((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-

methanobenzo[d][1,3,2]dioxaborol-2-yl)pentyl)amino)propan-2-yl)benzamide (70)



The obtained crude product was directly used in the next reaction without purification.

2,5-dichloro-N-((S)-3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-1-oxo-1-(((R)-2-(p-

tolyl)-1-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-

methanobenzo[d][1,3,2]dioxaborol-2-yl)ethyl)amino)propan-2-yl)benzamide (7p)



The obtained crude product was directly used in the next reaction without purification.

#### 2. <sup>1</sup>H NMR, <sup>13</sup>C NMR and mass spectra of target compounds 8a-8m, 8o-8p

Compounds **8a-8m** and **8o-8p** were prepared from the corresponding starting materials described for the synthesis of **8n**.

((R)-3-methyl-1-((S)-2-(2-morpholinoacetamido)-3-phenylpropanamido) butyl)boronic acid (8a)



Yellow foam solid (0.49 g, 84.6%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD)  $\delta$  0.85 (dd,  $J_1$  = 4.8 Hz,  $J_2$  = 6.5 Hz, 6H), 1.17 (t, J = 7.3 Hz, 2H), 1.40 (dd,  $J_1$  = 6.7 Hz,  $J_2$  = 13.4 Hz, 1H), 2.69 (t, J = 7.4 Hz, 1H), 3.03-3.21 (m, 4H), 3.23 (d, J = 7.3 Hz, 1H), 3.49 (d, J = 12.0 Hz, 1H), 3.73-3.87 (m, 2H), 3.94-4.09 (m, 4H), 4.87 (d, J = 8.0 Hz, 1H), 7.22-7.36 (m, 5H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD)  $\delta$  22.14, 23.67, 26.64, 38.51, 40.63, 47.87, 52.84, 58.02, 64.62, 128.29, 129.75, 130.54, 136.86, 165.12, 176.92. MS (ESI) m/z 404.6 [M-H]<sup>-</sup>. HRMS (ESI): calcd for C<sub>20</sub>H<sub>32</sub>BN<sub>3</sub>NaO<sub>5</sub> [M+Na]<sup>+</sup>, 428.2330; found, 428.2337.

#### (R)-(3-methyl-1-(2-(2-morpholinoacetamido)acetamido)butyl)boronic acid (8b)



Yellow foam solid (0.25 g, 69.1%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD)  $\delta$  0.93 (d, *J* = 6.6 Hz, 6H), 1.32-1.39 (m, 2H), 1.63-1.70 (m, 1H), 2.78 (t, *J* = 7.5 Hz, 1H), 3.19-3.29 (m, 2H), 3.56 (d, *J* = 12.4 Hz, 2H), 3.81-3.89 (m, 2H), 4.06 (d, *J* = 17.1 Hz, 4H), 4.15 (s, 2H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD)  $\delta$  22.49, 23.54, 26.73, 40.75, 53.93, 54.30, 58.20, 64.69, 166.05, 166.13. MS (ESI) m/z 314.1 [M-H]<sup>-</sup>. HRMS (ESI): calcd for C<sub>13</sub>H<sub>26</sub>BN<sub>3</sub>NaO<sub>5</sub> [M+Na]<sup>+</sup>, 338.1860; found, 338.1864.

((R)-1-((S)-3,3-dimethyl-2-(pyrazine-2-carboxamido)butanamido)-3methylbutyl)boronic acid (8c)



Yellow foam solid (0.15 g, 56.3%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD)  $\delta$  0.93 (dd,  $J_1$  = 1.5 Hz,  $J_2$  = 6.5 Hz, 6H), 1.12 (s, 9H), 1.33-1.39 (m, 2H), 1.65 (dd,  $J_1$  = 6.6 Hz,  $J_2$  = 13.4 Hz, 1H), 2.74 (dd,  $J_1$  = 6.5 Hz,  $J_2$  = 8.8 Hz, 1H), 4.72 (d, J = 6.2 Hz, 1H), 8.73 (s, 1H), 8.85 (d, J = 2.3 Hz, 1H), 9.25 (s, 1H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD)  $\delta$  22.27, 23.80, 26.88, 27.02, 35.93, 41.15, 58.64, 144.84, 144.87, 145.24, 149.19, 164.70, 176.00. MS (ESI) m/z 349.4 [M-H]<sup>-</sup>. HRMS (ESI) calcd for C<sub>16</sub>H<sub>27</sub>BN<sub>4</sub>NaO<sub>4</sub> [M+Na]<sup>+</sup>, 373.2021; found, 373.2014.

((R)-1-((S)-3,3-dimethyl-2-(5,6,7,8-tetrahydronaphthalene-1carboxamido)butanamido)-3-methylbutyl)boronic acid (8d)



Yellow foam solid (0.19 g, 56.7%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD)  $\delta$  0.94 (dd,  $J_I$  = 1.0 Hz,  $J_2$  = 6.5 Hz, 6H), 1.10 (s, 9H), 1.34-1.39 (m, 2H), 1.62-1.71 (m, 1H), 1.78 (d, J = 13.0 Hz, 4H), 2.75 (dd,  $J_I$  = 6.0 Hz,  $J_2$  = 9.3 Hz, 1H), 2.80 (d, J = 5.3 Hz, 4H), 4.70 (s, 1H), 7.09-7.17 (m, 3H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD)  $\delta$  22.15, 23.91, 23.94, 24.09, 27.05, 27.12, 27.84, 30.69, 35.49, 41.30, 59.04, 125.34, 126.40, 131.86, 135.27, 137.72, 139.06, 173.59, 176.97. MS (ESI) m/z 401.5 [M-H]<sup>-</sup>. HRMS (ESI) calcd for C<sub>22</sub>H<sub>35</sub>BN<sub>2</sub>NaO<sub>4</sub> [M+Na]<sup>+</sup>, 425.2586; found, 425.2577.

((R)-1-((S)-2-(2,5-dichlorobenzamido)-3,3-dimethylbutanamido)-3methylbutyl)boronic acid (8e)



White foam solid (0.15 g, 68.9%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD)  $\delta$  0.96 (dd,  $J_1$  = 2.1 Hz,  $J_2$  = 6.6 Hz, 6H), 1.13 (s, 9H), 1.32 (dd,  $J_1$  = 7.9 Hz,  $J_2$  = 15.5 Hz, 2H), 1.65-

1.73 (m, 1H), 2.78 (dd,  $J_1 = 6.1$  Hz,  $J_2 = 9.3$  Hz, 1H), 4.73 (s, 1H), 7.45–7.50 (m, 3H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD)  $\delta$  22.14, 23.91, 27.04, 27.08, 35.66, 41.27, 59.15, 129.8, 130.46, 132.14, 132.43, 133.89, 138.63, 168.61, 176.45. MS (ESI) m/z 415.3[M-H]<sup>-</sup>. HRMS (ESI) calcd for C<sub>18</sub>H<sub>27</sub>BCl<sub>2</sub>N<sub>2</sub>NaO<sub>4</sub> [M+Na]<sup>+</sup>, 439.1336; found, 439.1346.

((R)-1-((S)-2-(2,5-dichlorobenzamido)-3-(2-fluorophenyl)propanamido)-3methylbutyl)boronic acid (8f)



White foam solid (0.46 g, 62.8%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD)  $\delta$  0.85 (t, *J* = 6.2 Hz, 6H), 1.17 (t, *J* = 7.3 Hz, 2H), 1.34-1.43 (m, 1H), 2.72 (t, *J* = 7.6 Hz, 1H), 3.22 (d, *J* = 8.0 Hz, 2H), 5.05 (t, *J* = 8.0 Hz, 1H), 7.13 (dd, *J*<sub>1</sub> = 8.2 Hz, *J*<sub>2</sub> = 14.8 Hz, 2H), 7.32 (dd, *J*<sub>1</sub> = 7.6 Hz, *J*<sub>2</sub> = 14.7 Hz, 3H), 7.42-7.48 (m, 2H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD)  $\delta$  21.99, 23.89, 26.70, 32.07, 40.93, 51.59, 116.32, 116.54, 123.88, 125.52, 129.86, 130.64, 132.32, 132.56, 133.12, 133.88, 138.10, 161.57, 164.01, 168.11, 176.51. MS (ESI) m/z 467.7 [M-H]<sup>-</sup>. HRMS (ESI): calcd for C<sub>21</sub>H<sub>24</sub>BCl<sub>2</sub>FN<sub>2</sub>NaO<sub>4</sub> [M+Na]<sup>+</sup>, 491.1086; found, 491.1095.

((R)-1-((S)-2-(2,5-dichlorobenzamido)-3-(2,6-difluorophenyl)propanamido)-3methylbutyl)boronic acid (8g)



White foam solid (0.11 g, 55.5%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD)  $\delta$  0.88 (dd,  $J_I$  = 1.9 Hz,  $J_2$  = 6.5 Hz, 6H), 1.22 (t, J = 7.4 Hz, 2H), 1.40-1.48 (m, 1H), 2.75 (t, J = 7.6 Hz, 1H), 3.23 (dd,  $J_I$  = 8.1 Hz,  $J_2$  = 13.8 Hz, 1H), 3.28-3.36 (m, 1H), 5.09 (t, J = 7.9 Hz, 1H), 6.95-7.04 (m, 2H), 7.31-7.41 (m, 2H), 7.43-7.48 (m, 2H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD)  $\delta$  23.85, 25.69, 26.73, 30.71, 40.93, 50.93, 112.33, 112.39, 112.52,

112.58, 129.84, 130.63, 130.79, 132.35, 132.58, 133.88, 137.99, 161.94, 162.02, 164.40, 164.48, 168.07, 176.21. MS (ESI) m/z 485.6 [M-H]<sup>-</sup>. HRMS (ESI): calcd for C<sub>21</sub>H<sub>23</sub>BCl<sub>2</sub>F<sub>2</sub>N<sub>2</sub>NaO<sub>4</sub> [M+Na]<sup>+</sup>, 509.0992; found, 509.1001.

((R)-1-((S)-2-(2,5-dichlorobenzamido)-3-phenylpropanamido)-3-

methylbutyl)boronic acid (8h)



White foam solid (0.31 g, 61.9%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD)  $\delta$  0.85 (t, J = 6.8 Hz, 6H), 1.26-1.33 (m, 2H), 1.37 (dd,  $J_I = 7.0$  Hz,  $J_2 = 13.6$  Hz, 1H), 2.65-2.73 (m, 1H), 3.12-3.19 (m, 2H), 4.94-5.01 (m, 1H), 7.24-7.37 (m, 6H), 7.45 (d, J = 1.1 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD)  $\delta$  21.92, 23.91, 26.67, 38.55, 40.88, 53.03, 128.30, 129.73, 129.87, 130.55, 130.62, 132.28, 132.53, 133.84, 136.98, 138.13, 168.14, 176.83. MS (ESI) m/z 449.6[M-H]<sup>-</sup>. HRMS (ESI): calcd for C<sub>21</sub>H<sub>25</sub>BCl<sub>2</sub>N<sub>2</sub>NaO<sub>4</sub> [M+Na]<sup>+</sup>, 473.1180; found, 473.1188.

((R)-1-((S)-2-cyclohexyl-2-(2,5-dichlorobenzamido)acetamido)-3methylbutyl)boronic acid (8i)



Yellow foam solid (0.16 g, 71.4%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  0.65-0.83 (m, 3H), 0.83-0.96 (m, 3H), 1.01-1.27 (m, 5H), 1.31-1.51 (m, 2H), 1.52-1.62 (m, 1H), 1.67 (d, *J* = 11.3 Hz, 1H), 1.75 (s, 5H), 2.80-3.09 (m, 1H), 4.39-4.75 (m, 1H), 7.29-7.43 (m, 2H), 7.50-7.62 (m, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  23.05, 25.83, 28.85, 29.35, 29.64, 39.98, 40.62, 56.60, 58.10, 129.02, 129.62, 131.34, 133.10, 135.82, 135.98, 165.34, 172.59. MS (ESI) m/z 441.2 [M-H]<sup>-</sup>. HRMS (ESI) calcd for C<sub>20</sub>H<sub>29</sub>BCl<sub>2</sub>N<sub>2</sub>NaO<sub>4</sub> [M+Na]<sup>+</sup>, 465.1493; found, 465.1497.

((R)-1-((R)-2-cyclohexyl-2-(2,5-dichlorobenzamido)acetamido)-3-

methylbutyl)boronic acid (8j)



Yellow foam solid (0.17 g, 68.5%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  0.80 (d, J = 8.1 Hz, 3H), 0.82-0.90 (m, 3H), 1.13-1.29 (m, 5H), 1.29-1.45 (m, 2H), 1.47-1.58 (m, 1H), 1.68 (s, 1H), 1.83 (dd,  $J_1 = 23.0$  Hz,  $J_2 = 26.6$  Hz, 5H), 3.09 (d, J = 109.8 Hz, 1H), 4.50-4.81 (m, 1H), 7.28-7.88 (m, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  23.08, 25.65, 25.77, 26.09, 29.65, 39.86, 39.92, 57.29, 57.37, 129.17, 129.77, 131.17, 132.91, 136.00, 165.32, 172.40. MS (ESI) m/z 441.3 [M-H]<sup>-</sup>. HRMS (ESI) calcd for C<sub>20</sub>H<sub>29</sub>BCl<sub>2</sub>N<sub>2</sub>NaO<sub>4</sub> [M+Na]<sup>+</sup>, 465.1493; found, 465.1495.

((R)-1-((S)-2-(2,5-dichlorobenzamido)-3-(2,3-dihydrobenzo[*b*][1,4]dioxin-6yl)propanamido)-3-methylbutyl)boronic acid (8k)



Yellow foam solid (0.85 g, 52.4%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  0.76-0.83 (m, 3H), 0.83-0.91 (m, 3H), 1.29 (dd,  $J_1 = 8.8$  Hz,  $J_2 = 15.0$  Hz, 1H), 1.39-1.56 (m, 2H), 2.92 (d, J = 35.0 Hz, 1H), 3.09 (t, J = 6.2 Hz, 2H), 4.21 (d, J = 5.5 Hz, 4H), 4.91 (t, J = 19.8 Hz, 1H), 6.66 (dd,  $J_1 = 12.5$  Hz,  $J_2 = 27.4$  Hz, 1H), 6.71-6.80 (m, 2H), 7.21-7.59 (m, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  22.98, 25.82, 37.32, 39.90, 50.52, 52.82, 64.25, 117.35, 118.30, 122.46, 128.74, 129.09, 129.48, 131.25, 132.94, 135.75, 142.68, 143.36, 165.24, 172.64. MS (ESI) m/z 507.2 [M-H]<sup>-</sup>. HRMS (ESI) calcd for C<sub>23</sub>H<sub>27</sub>BCl<sub>2</sub>N<sub>4</sub>NaO<sub>6</sub> [M+Na]<sup>+</sup>, 531.1325; found, 531.1246.

((R)-1-((S)-3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-(5,6,7,8tetrahydronaphthalene-1-carboxamido)propanamido)-3-methylbutyl)boronic acid (8l)



Yellow foam solid (0.47 g, 59.2%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  0.83 (d, *J* = 4.7 Hz, 3H), 0.86 (d, *J* = 10.6 Hz, 3H), 1.41-1.51 (m, 2H), 1.52-1.64 (m, 1H), 1.73 (s, 4H), 2.50-2.67 (m, 2H), 2.73 (s, 2H), 2.88-2.98 (m, 1H), 2.99-3.15 (m, 2H), 4.11-4.31 (m, 4H), 4.82-4.99 (m, 1H), 6.44-6.62 (m, 1H), 6.63-6.82 (m, 3H), 6.99-7.10 (m, 3H), 7.37-7.97 (m, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  22.41, 22.54, 22.87, 25.82, 26.54, 29.71, 31.88, 39.97, 52.20, 52.69, 64.25, 117.23, 118.17, 122.18, 124.03, 125.12, 129.14, 131.09, 134.83, 135.61, 138.02, 142.49, 143.37, 170.43, 173.44. MS (ESI) m/z 493.2 [M-H]<sup>-</sup>. HRMS (ESI) calcd for C<sub>23</sub>H<sub>27</sub>BCl<sub>2</sub>N<sub>2</sub>NaO<sub>6</sub> [M+Na]<sup>+</sup>, 517.2485; found, 517.2480.

((R)-1-((S)-3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-(pyrazine-2carboxamido)propanamido)-3-methylbutyl)boronic acid (8m)



Yellow foam solid (0.14 g, 63.2%). <sup>1</sup>H NMR (400 MHz, DMSO- $d_6$ )  $\delta$  0.74 (d, J = 5.4 Hz, 3H), 0.84 (m, 3H), 1.02-1.21 (m, 1H), 1.30-1.41 (m, 1H), 1.51 (dd,  $J_1$  = 6.6 Hz,  $J_2$  = 13.1 Hz, 1H), 2.82-3.01 (m, 2H), 3.02-3.15 (m, 1H), 4.14 (d, J = 5.5 Hz, 4H), 4.62-4.88 (m, 1H), 6.64 (d, J = 10.7 Hz, 2H), 6.71 (d, J = 4.2 Hz, 1H), 8.62 (t, J = 8.3 Hz, 1H), 8.68-8.78 (m, 1H), 8.79-8.93 (m, 2H), 9.05-9.17 (m, 1H). <sup>13</sup>C NMR (100MHz, DMSO- $d_6$ )  $\delta$  22.96, 25.89, 31.88, 37.60, 52.41, 58.34, 64.21, 117.30,

118.18, 122.35, 128.72, 142.68, 142.74, 143.44, 143.78, 144.22, 147.44, 162.94, 172.84. MS (ESI) m/z 441.1 [M-H]<sup>-</sup>. HRMS (ESI) calcd for C<sub>21</sub>H<sub>27</sub>BN<sub>4</sub>NaO<sub>6</sub> [M+Na]<sup>+</sup>, 465.1919; found, 469.1932.

((R)-1-((S)-2-(2,5-dichlorobenzamido)-3-(2,3-dihydrobenzo[b][1,4]dioxin-6yl)propanamido)pentyl)boronic acid (80)



Yellow foam solid (0.03 g, 46.4%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  0.82 (s, 3H), 1.25 (s, 2H), 1.27-1.38 (m, 2H), 1.52-2.07 (m, 2H), 2.60-3.00 (m, 1H), 3.06 (s, 2H), 4.20 (d, *J* = 5.4 Hz, 4H), 4.86 (d, *J* = 68.6 Hz, 1H), 6.71 (dd, *J*<sub>1</sub> = 13.6 Hz, *J*<sub>2</sub> = 29.0 Hz, 3H), 7.04 (d, *J* = 38.7 Hz, 1H), 7.17-7.25 (m, 1H), 7.27-7.44 (m, 2H), 7.47-7.86 (m, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  14.25, 22.49, 22.82, 29.83, 36.05, 55.36, 64.44, 117.64, 118.41, 122.53, 129.21, 129.27, 130.05, 131.45, 133.18, 133.32, 142.88, 143.69, 165.12, 171.26. MS (ESI) m/z 507.1 [M-H]<sup>-</sup>. HRMS (ESI): calcd for C<sub>23</sub>H<sub>27</sub>BCl<sub>2</sub>N<sub>2</sub>NaO<sub>6</sub> [M+Na]<sup>+</sup>, 531.1236; found, 531.1239.

((R)-1-((S)-2-(2,5-dichlorobenzamido)-3-(2,3-dihydrobenzo[b][1,4]dioxin-6yl)propanamido)-2-(p-tolyl)ethyl)boronic acid (8p)



Yellow foam solid (0.03 g, 27.9%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.23 (s, 3H), 2.73 (d, *J* = 23.3 Hz, 2H), 2.91-3.05 (m, 2H), 3.05-3.23 (m, 1H), 3.97-4.33 (m, 4H), 4.71-5.02 (m, 1H), 6.26-6.46 (m, 1H), 6.58-6.86 (-Ph, m, 4H), 6.85-7.00 (-Ph, m, 3H), 7.01-7.11 (-Ph, m, 3H), 7.32-7.93 (-CONH, m, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 22.52, 29.74, 36.13, 46.62, 52.26, 64.27, 117.34, 118.17, 122.19, 128.82, 134.91, 135.20, 137.50, 138.07, 143.56, 170.20, 174.00. MS (ESI) m/z 555.4 [M-H]<sup>-</sup>. HRMS (ESI): calcd for  $C_{27}H_{27}BN_2NaO_6$  [M+Na]<sup>+</sup>, 579.1236; found, 579.1237.

### 3. <sup>1</sup>H NMR spectra of intermediate compounds

### Compound 1c



Compound 2a





Compound 2b

Compound 2c





Compound 2e





Compound 3a





Compound 3c



Compound **3b** 



Compound 3e





Compound 6a



Compound 3f



Compound 6c





Compound 6d

Compound 6e





Compound 7a

Compound 7b





Compound 7c

#### Compound 7d





Compound 7e

Compound 7f





### Compound 7g

#### Compound 7h







## Compound 7j





### Compound 7k

### Compound 71





### Compound 7m

### Compound 7n





### 4. <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra of final compounds













Compound 8c



Compound 8d



40 30

20 10

0 -10

50

60

Compound 8e

200 190 180 170 160

150 140 130 120 110

100 90 f1 (ppm) 80 70



Compound 8f



Compound 8g





### Compound 8h



Compound 8i



Compound 8j



Compound 8k



Compound 81



Compound 8m



Compound 8n



Compound 80



Compound 8p



Compound 8q



Compound 8r



Compound 8s





### Compound 8t